EUCTR2011-000299-33-DE进行中（未招募）不适用
Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •*women = 18 years
- •*ECOG Performance Status = 2
- •*Before performance of study specific actions or assessment the patient has to be informed, has signed the written consent and is willing to follow the requirements concerning treatment and follow-up.
- •Comment: Procedures which are according to common clinical routine and having been performed before having given written informed consent may be used for the purpose of screening procedures or initial medical assessment as long as these procedures follow the protocol.
- •*required: negative pregnancy test in fertile women
- •Stratum A – Ovarian Cancer:
- •-Histologically confirmed Ovarian Cancer
- •-platin-refractory relapsed disease: progression within a platin-based chemotherapy or within 6 months after completion of a platin-based chemotherapy
- •-prior treatment with a taxan-based scheme
- •-minimum of one measurable or non-measurable tumor lesion (according to RECIST 1.1 criteria)
- •-not more than 2 previous chemotherapies or cytostatic therapies (i.e. monoclonal antibodies, cytokines, signal transduction inhibitors)
- •Stratum B – Endometrian Cancer:
- •-Histologically confirmed Endometrian Cancer
- •-advanced (FIGO III or IV) or relapsed diseases not amenable to potentially curative treatment with local surgery and/or radiation therapy
- •-prior endocrine therapy is allowed
- •-prior adjuvant chemotherapy is allowed
- •-minimum of one measurable or non-measurable tumor lesion (according to RECIST 1.1 criteria)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •*ECOG > 2
- •*prior therapy with mTOR-Inhibitor
- •*cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal transduction inhibitors), cytotoxical chemotherapy or endocrine therapy or radiation at the same time
- •*current or recent treatment with another study drug and/or participation in another clinical study within 28 days prior to first dose of study treatment
- •* chemotherapy or cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal transduction inhibitors) or radiation within 28 days prior to start of study treatment
- •*known or supposed hypersensitivity compared to study medication
- •*acute or chronical infection
- •*Second malignancy which influences the prognosis of the patient
- •*inadequate renal function (Creatinin >1.5 x ULN)
- •*inadequate liver function (AST, ALT, GGT >2.5 x ULN or >5.0 x ULN in the presence of liver metastasis; Bilirubin >1.5 x ULN)
- •*platelets < 100.000 /µl; ANC < 1.500 /µl
- •*cachectic patients with weight < 45kg
- •*patients who need parenteral nutrition
- •*patients with ileus within the last 28 days
- •*one of the following diseases within 12 months prior to first study treatment: myocardial infarction, severe/unstable angina, bypass-surgery of the coronar- or peripheral vessels, symptomatic heart insufficiency, cerebrovascular insult, transient ischemic attack (TIA), pulmonary embolism, deep venous thrombosis, other thromboembolic events
- •*current treatment with CYP3A4-Inhibitors (i.e. protease inhibitors, antimycotics, calcium channel blocker, macrolide antibiotics, Cimetidin) or -inductors (i.e. Carbamazepin, Phenobarbital, Phenytoin, Rifampicin, amber)
- •*uncontrolled hypertension (>150/100 mmHg despite optimal medicinal treatment)
- •*current cardiac arrhythmias (NCI CTCAE grade =2), atrial fibrillation, prolongation of QTc >470 msec
- •*left ventricular ejection fraction (LVEF) =50% defined by ECHO
- •*NCI CTCAE grade 3 hemorrhage within 4 weeks prior to beginning of treatment
- •*symptoms which indicate brain metastases, spinal cord compression or give new indications for brain- or leptomeningeal metastases
- •*HIV positive or manifested AIDS-disease
- •*patients with other severe diseases who represent an inadequate risk for study participation
- •Applicable only for patients with no hysterectomy and/or bilateral adnexectomy prior to start of study.
- •*lactation
- •*potential fertile women without adequate contraception (potential fertile women must use one of the following adequate contraception: complete abstinence, intrauterine spiral or another method with a failure quote <1% per year)
- •*life expectancy <3 months
- •*neurological or psychiatric diseases or drugs or alcohol abuse which suppose no adequate comprehension and consequently no effective consent to study participation or no acceptable compliance during the study
- •*predictable problems with the compliance to appointments for examinations
研究者
相似试验
进行中（未招募）
1 期
Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique. - VESTOREUCTR2009-011049-15-FRInstitut Bergonié - Département d’Oncologie Médicale
进行中（未招募）
不适用
A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma - Temsirolimus in PZNSPatients with refractory and recidivated primary CNS lymphomaEUCTR2009-011277-33-DECharité - University Hospital of Berlin
进行中（未招募）
不适用
CESAR Study in Prostrate Cancer with Temsirolimus added to standard Docetaxel therapy (CEPTAS)castration resistant prostate cancer (CRPC)MedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018370-21-DECESAR Central European Society for Anticancer Drug Research EWIV122
进行中（未招募）
不适用
Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer - temsirolimus-RCC-imagingadvanced (stage IV or recurrent disease) RCCEUCTR2009-012802-38-NLniversity Medical Centre Nijmegen St Radboud
招募中
2 期
Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancerrenal cell carcinomaNL-OMON33063niversitair Medisch Centrum Sint Radboud50